BioLife Discloses Shareholder Lawsuits and Supplemental Proxy Disclosures Ahead of Merger Vote
BLFS has more than doubled off its 52-week low of $17.86.
Summary
BioLife Solutions disclosed two shareholder lawsuits challenging the adequacy of its merger proxy disclosures and issued supplemental disclosures regarding executive compensation terms. The merger vote is scheduled for October 5, 2026.
Updates
· SEC 425 — Repligen filed a 425 with the same supplemental disclosures and shareholder suit details.
Key Events · Legal and Risk Events · BLFS
-
Shareholder Lawsuits Filed
Two complaints filed September 10, 2026 in New York Supreme Court (Richard Lawrence v. BioLife Solutions, Inc., et al., No. 655180/2026; James Walsh v. BioLife Solutions, Inc., et al., No. 655175/2026) allege the Definitive Proxy Statement misrepresents or omits material information regarding financial projections, financial advisor analyses, and conflicts of interest. The complaints seek to enjoin the merger or rescind it if consummated.
-
Supplemental Proxy Disclosures
BioLife and Repligen issued supplemental disclosures to the Proxy Statement/Prospectus, including updates on post-merger employment negotiations with Dr. Mathew, Mr. Berard, and Mr. Werner, and changes to severance payment terms from double-trigger to single-trigger for named executive officers.
-
Merger Vote Imminent
The special meeting of BioLife stockholders to vote on the Repligen merger is scheduled for October 5, 2026 at 9:00 a.m. Eastern Time — five days after this filing. The merger consideration is $11.25 cash plus 0.1442 shares of Repligen common stock per BioLife share.
-
Potential Excise Tax Reimbursements
Repligen may make tax reimbursement payments to Mr. Wichterman and Mr. Werner for excise taxes under Section 4999 of the Code, which are not currently determinable but may be material to those individuals.
Analysis · BLFS · Industrial Applications And Services
Two shareholder lawsuits filed September 10, 2026 allege the Definitive Proxy Statement misrepresents or omits material information about financial projections, financial advisor analyses, and conflicts of interest. The complaints seek to enjoin the Repligen merger or rescind it if consummated. BioLife also issued supplemental disclosures regarding post-merger employment negotiations and changes to severance payment terms for named executive officers. The merger vote is scheduled for October 5, 2026 — five days from this filing — so any litigation risk or disclosure deficiency could affect the outcome.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLFS was trading at $39.33 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $17.86 to $39.76. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.